Universal reference book for medicines
Product name: DARDUM

Active substance: cefoperazone

Type: Third generation cephalosporin

Manufacturer: LISAPHARMA (Italy)
Description of the active substance:
This information is a reference and it is not enough that the drug was prescribed by a doctor.
Cephalosporin antibiotic III generation of a broad spectrum of action.
Has a bactericidal effect by inhibiting the synthesis of the bacterial cell wall. Cefoperazone acetylates membrane-bound transpeptidases, disrupting, cross-linking peptidoglycans, necessary to ensure the strength and rigidity of the cell wall.
It is active against aerobic, anaerobic, gram-positive and gram-negative bacteria, as well as against Pseudomonas aeruginosa.

Resistant to the action of most ОІ-lactamases.

The binding with plasma proteins is 82-93%.
Distributed in tissues and body fluids, reaching C max in the bile in 1-2 hours. Poorly penetrates the BBB, penetrates the placental barrier, excreted in breast milk. It is excreted with bile. Up to 30% of the dose is excreted in the urine unchanged for 12-24 hours.
Infectious-inflammatory diseases caused by microorganisms sensitive to cefoperazone, incl.
diseases of the upper and lower respiratory tract, genitourinary system infections, peritonitis, cholecystitis and other abdominal infections, sepsis, meningitis, skin and soft tissue infections, pelvic infection.
Prevention of infectious complications after abdominal, gynecological, cardiovascular and orthopedic operations.

Enter in / in or / m.

A single dose for intravenous administration for adults is 1-4 g / day, the interval between the introduction of 12 hours. Depending on the etiology of the disease, perhaps an IM injection of 500 mg once.

Children - 50-200 mg / kg / day, the frequency of administration - 2 times / day.

The maximum daily intake for adults is 12 g.

On the part of the digestive system: nausea, vomiting, diarrhea, transient increase in hepatic transaminase activity, cholestatic jaundice, hepatitis, pseudomembranous colitis.

Allergic reactions: skin rash, itching, eosinophilia;
rarely - angioedema.
From the hemopoietic system: with prolonged use in high doses, changes in the pattern of peripheral blood (leukopenia, neutropenia, thrombocytopenia, hemolytic anemia) are possible.

From the coagulation system: hypoprothrombinemia.

From the side of the urinary system: interstitial nephritis.

Effects caused by chemotherapeutic action: Candidiasis.

Local reactions: phlebitis (with iv introduction), soreness at the injection site (with an / m introduction).

Severe renal failure, pregnancy, lactation, hypersensitivity to cephalosporins and other beta-lactam antibiotics.

Contraindicated in pregnancy and lactation (breastfeeding).

Contraindicated in severe renal failure.

With caution apply cefoperazone for violations of the liver (with a simultaneous violation of the liver and kidneys needed dose correction).

Caution is applied to cefoperazone for violations of liver function (with a simultaneous violation of liver and kidney function, dose adjustment is necessary), as well as in patients with a history of bleeding.

In patients with hypersensitivity to penicillins, allergic reactions to cephalosporin antibiotics are possible.

During the application of cefoperazone, a false positive urine reaction to glucose is possible.

During the treatment with cefoperazone, alcohol should be avoided, since
it is possible to develop effects similar to the action of disulfiram (abdominal cramps, nausea, vomiting, headache, hypotension, dyspnea, tachycardia).
Cefoperazone, suppressing the intestinal flora, interferes with the synthesis of vitamin K. Therefore, with the simultaneous appointment with drugs that reduce platelet aggregation (NSAIDs, salicylates, sulfinpyrazone), the risk of bleeding increases.
For the same reason, with simultaneous use with anticoagulants, there is an increase in anticoagulant activity.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y

Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!